Strumento inattivo

Azioni Anacor Pharmaceuticals Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing	26/05/16
Ryan & Maniskas, LLP : Announces Investigation of Anacor Pharmaceuticals, Inc.	18/05/16
Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information	17/05/16
Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information	16/05/16
Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel	16/05/16

Dirigenti	Titolo	Età	Da
Douglas Giordano CEO	Chief Executive Officer	61	24/06/16
Jacob John Plattner CTO	Chief Tech/Sci/R&D Officer	77	01/02/04
Margaret M. Madden BRD	Director/Board Member	-	24/06/16

Amministratori	Titolo	Età	Da
Douglas Giordano CEO	Chief Executive Officer	61	24/06/16
Bryan Supran BRD	Director/Board Member	-	24/06/16
Margaret M. Madden BRD	Director/Board Member	-	24/06/16

Settore

	Variaz. 1 gen.	Capi.
IQVIA HOLDINGS INC.	+1,51%	42,75 Mrd
LONZA GROUP AG	+49,22%	41,61 Mrd
MODERNA, INC.	+8,57%	41,34 Mrd
CELLTRION, INC.	-12,36%	26,59 Mrd
ICON PUBLIC LIMITED COMPANY	+8,92%	25,49 Mrd
ALNYLAM PHARMACEUTICALS, INC.	-25,13%	18,12 Mrd
MEDPACE HOLDINGS, INC.	+29,17%	12,24 Mrd
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3,12%	11,76 Mrd
UNITED THERAPEUTICS CORPORATION	+6,35%	11 Mrd